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EVIDENCE-BASED ANSWER
A first, consider possible causes of  the inadequate response, then 
weigh treatment options in light of the 
characteristics of the individual patient and 
therapy. When managing a patient with 
nonpsychotic depression and inadequate 
response to the maximum dose of a single 
antidepressant, the physician should fi rst 
identify factors that may contribute to the 
poor response, such as suboptimal dosage 
resulting from nonadherence, inadequate 
duration of therapy, and comorbid medical 
and psychiatric conditions (strength of rec-
ommendation [SOR]: C, expert opinion).
Th e literature supports several treat-
ment alternatives, including augmentation 
with cognitive therapy, switch therapy, and 
combination-augmentation therapy; not 
enough studies exist to recommend the best 
treatment. All options reviewed produced a 
20% to 50% remission rate (SOR: B, system-
atic reviews and randomized controlled tri-
als [RCTs]). 
Physicians should consider the pa-
tient’s clinical history and preferences, 
along with drug toxicity, potential drug in-
teractions, and cost when making treatment 
decisions (SOR: C, expert opinion).
Evidence summary
A recent study randomized 158 patients who 
didn’t respond to antidepressant therapy to 
either cognitive therapy with clinical man-
agement or clinical management alone.1 Th e 
cognitive therapy group had a 29% cumula-
tive relapse rate at 68 weeks, compared with 
47% in the clinical management control group 
(number needed to treat [NNT]=6). 
A crossover RCT compared 12 weeks of 
the cognitive behavioral analysis system of psy-
chotherapy (CBASP) in 61 patients who had 
failed to respond to a 12-week course of ne-
fazodone with 12 weeks of nefazodone treat-
ment in 79 patients who hadn’t responded to 
12 weeks of CBASP.2 Remission rates were 
comparable in the 2 crossover groups (28% for 
nefazodone vs 25% for CBASP; P=.92). 
Drugs may produce a faster response
Th e Sequenced Treatment Alternatives to 
Relieve Depression (STAR*D) trial compared 
augmentation with as many as 16 sessions of 
cognitive therapy with pharmacologic aug-
mentation and switch strategy among 65 pa-
tients who had failed to respond to 14 weeks 
of citalopram.3 
Th e investigators concluded that aug-
mentation with cognitive therapy or phar-
macologic therapy was equally eff ective, but 
pharmacologic augmentation produced a 
more rapid response (mean time to fi rst re-
mission for cognitive therapy=53.3 days, 
compared with 40.1 days for pharmacologic 
therapy; P=.022). Patients who were switched 
to cognitive therapy had similar outcomes 
to patients who were switched to alternative 
antidepressants (remission rates=25% and 
27.9%, respectively; P=.6881), but reported 
fewer adverse eff ects (0% vs 48%). 
When an SSRI fails …
A recent systematic review of 8 RCTs (includ-
ing STAR*D) and 23 open studies concluded 
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that after a fi rst failure of a selective serotonin 
reuptake inhibitor (SSRI), any switch within or 
between classes of antidepressant is legitimate 
and equally eff ective.4
❚ Switching within the same class of an-
tidepressant. Th e STAR*D study, an unblinded 
RCT, reported that patients (N=238; median 
age 41 years) who were switched to sertraline 
(as much as 200 mg per day for 14 weeks) when 
they didn’t tolerate or respond adequately 
to citalopram had remission rates of 17.6% 
on the Hamilton Rating Scale for Depression 
(HAM-D) and 26.6% on the Quick Inventory of 
Depressive Symptomatology (QIDS).5
❚  Switching to a different class of anti-
depressant. In a multisite study, outpatients 
who failed to respond to 12-week, double-blind 
treatment with either sertraline (n=117) or 
imipramine (n=51) were randomized to an ad-
ditional 12 weeks of double-blinded treatment 
with the alternate medication. Investigators 
reported a 60% response rate in the sertraline 
switch group and a 44% response rate in the 
imipramine switch group.6
In the STAR*D study, patients who didn’t 
tolerate or failed to respond to as many as 
12 weeks of citalopram were switched to 
sustained-release (SR) bupropion, sertraline, 
or extended-release (ER) venlafaxine for as 
long as 14 weeks.5 Th e bupropion-SR switch 
group (n=239, up to 400 mg per day) had re-
mission rates of 21.3% (HAM-D) and 25.5% 
(QIDS); the sertraline switch group (n=238, 
up to 200 mg per day) had remission rates of 
17.6% (HAM-D) and 26.6% (QIDS); and the 
venlafaxine-ER switch group (n=250, up to 
375 mg per day) had remission rates of 24.8% 
(HAM-D) and 25% (QIDS). Th ere were no 
clinically or statistically signifi cant diff erences 
among the groups. 
Response declines 
with multiple switches
Patients who didn’t respond to this treatment 
arm and were switched again to either mir-
tazapine (n=114, as much as 60 mg per day) 
or nortriptyline (n=121, as much as 200 mg 
per day) had a much less favorable response 
(mirtazapine 12.3% vs nortriptyline 19.8%; 
NNT nortriptyline-mirtazapine=13).7 
Patients who failed to respond to this 
treatment arm were randomized to either 
tranylcypromine (n=58, mean 36.9 mg per 
day) or venlafaxine plus mirtazapine (n=51, 
mean 210.3 and 35.7 mg per day, respec-
tively). Both groups had low remission rates 
(tranylcypromine 6.9%, venlafaxine plus 
mirtazapine 13.7%; NNT venlafaxine plus 
mirtazapine-tranylcypromine=15).8 
Lithium and T3 augmentation both work
A 1999 systematic review of 9 double-blind 
RCTs (N=234) reported that patients treated 
with lithium augmentation (250-1200 mg 
per day, or a serum level of 0.5 mmol/L for 
2 weeks) had a 45% improvement in depres-
sive symptoms (HAM-D), whereas the placebo 
group showed 18% improvement (NNT=3.7; 
95% confi dence interval [CI], 2.6-6.6).9 An up-
dated meta-analysis of 10 RCTs confi rmed the 
effi  cacy of lithium augmentation compared 
with placebo (41% vs 14.4% improvement; 
NNT=5).10
Recently, the STAR*D study (N=142) re-
ported that augmentation with either lithium 
or triiodothyronine (T3) after 2 antidepressant 
failures was equally eff ective (lithium response 
15.9%; T3 response 24.7%; NNT T3-lithium=11; 
P=.43). However, lithium was more often as-
sociated with side eff ects (number needed to 
harm [NNH]=7; P=.045).11
Bupropion and buspirone 
augmentation are comparable
An unblinded RCT found that patients who 
failed to respond to citalopram responded 
when augmented with either bupropion-SR 
or buspirone.12 After 8 weeks of treatment, the 
bupropion-SR group (n=565, as much as 400 
mg per day) had remission rates of 29.7% 
(HAM-D) and 39.9% (QIDS); the buspirone 
group (n=286, as much as 60 mg per day) had 
remission rates of 30.1% (HAM-D) and 26.9% 
(QIDS) (NNT buspirone-bupropion-SR=10). 
However, the bupropion-SR group had a lower 
dropout rate because of intolerance (12.5% vs 
20.6%; NNH=12; P<.009). 
Augmentation with 
atypical antipsychotics works
A recent meta-analysis of 10 RCTs (N=1500 
outpatients) assessed the eff ectiveness of aug-
menting various antidepressants with atypical 
antipsychotic agents (olanzapine, risperidone, 
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and quetiapine) for treatment-resistant major 
depressive disorder.13 Th e pooled remission 
and response rates favored augmentation with 
atypical antipsychotics over adjunctive placebo 
(47% vs 22.3% and 67.2% vs 35.4%, respectively). 
Another randomized study of 362 patients 
with incomplete response to standard antide-
pressant treatment found adjunctive aripip-
razole was eff ective and well tolerated (mean 
change in Montgomery-Åsberg Depression 
Rating Scale score: −8.8 in the aripiprazole 
group vs −5.8 in the placebo group; P<.001).14
Agents that aren’t recommended
Expert review doesn’t recommend routine 
use of other agents that have been studied for 
augmentation therapy, including dopami-
nergic drugs, pyschostimulants, modafi nil, 
anticonvulsants, inositol, opiates, estrogen, de-
hydroepiandrosterone, folate and S-adenosyl-
methionine, tryptophan, omega-3 fatty acid, 
pindolol, and monoamine oxidase inhibitors.15
Recommendations
Th e Institute for Clinical Systems Improve-
ment16 and the American Psychiatric Asso-
ciation17 recommend evaluating the dose and 
duration of medication, the patient’s adher-
ence to medication, and the accuracy of diag-
nosis or impact of comorbidities for patients 
who don’t respond adequately to treatment. 
Physicians also may consider other strate-
gies, including switch therapy, augmentation 
therapies, psychotherapy, and electroconvul-
sive therapy.                    JFP
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Frequently asked questions in the evaluation and 
management of overactive bladder
Patients often do not ask for medical help for overactive bladder (OAB) due to social stigma, misconceptions 
that OAB is an inevitable consequence of aging, and fear that the assessment and treatment will be more 
troublesome than the symptoms themselves.
A panel of 4 experts discusses the prevalence and pathophysiology of OAB, the role 
of behavioral and pharmacologic therapies, and how to recognize when referral to a 
urologist is appropriate.
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